Pharmaceutical News

RSS

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an acute migraine therapy that is not contraindicated in patients with a history, symptoms or signs of vascular disease and also offers improved efficacy and fast-acting oral delivery would earn a 45 percent patient share in the treatment of migraine, according to surveyed U.S. neurologists.

11 Mar 2010

iReminder’s white paper highlights key developments in HPV vaccine compliance and marketing efforts

Automated reminder and follow-up calls for HPV vaccinations increase adherence rates from 5% to over 20%, according to a new white paper published by iReminder, LLC. The Scotland National Health Service is the leader in HPV vaccination compliance, with rates as high as 92% for the first dose and 87.8% for the second dose. The laggard is Mississippi, USA where HPV vaccination rates are as low as 15.8%.

11 Mar 2010

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences.

11 Mar 2010

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.

11 Mar 2010

Non-smoked medical cannabis products needed, says National Drug Control Policy Deputy Director

Cannabis Science, Inc., a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.

11 Mar 2010

Advitech receives product licence for psoriasis treatment product

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today that the Natural Health Products Directorate (NHPD) has issued to Advitech, on March 8, 2010, a Natural Product Number (NPN) for one of its main products, XP-828L/Dermylex.

11 Mar 2010

WHO issues new guidelines for malaria treatment

The World Health Organization (WHO) is releasing new guidelines for the treatment of malaria, and the first ever guidance on procuring safe and efficacious anti-malarial medicines.

11 Mar 2010

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Human Genome Sciences, Inc. and BioInvent International AB today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

11 Mar 2010

Watson Pharmaceuticals resolves Actos patent litigation

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

11 Mar 2010

Forteo therapy may speed healing, improve patient outcomes after rotator cuff surgery

Tears in the shoulder's rotator cuff, a common sports injury, are painful and restricting. Surgery to repair the damage is successful for pain management, but in many patients it does not result in full recovery of function due to poor healing. New research shows an approved therapy for osteoporosis, Forteo, may speed healing and improve patient outcomes.

11 Mar 2010

Comparative research lags far behind approval-driven evaluations

A new study has found that few drug evaluations compare treatments in ways that help doctors make better decisions, Reuters reports.

11 Mar 2010

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Cannabis Science, Inc., a pioneering pharmaceutical cannabis company, is pleased to announce that it has formalized its agreement with a privately owned, highly specialized international FDA regulatory compliance firm. The compliance firm will review and prepare technical data for Cannabis Science's FDA Pre-Investigative New Drug submission package for its Veterans PTSD Project.

11 Mar 2010

Majority of nurse practitioners recommend dietary supplements for overall health and wellness

Eighty-five percent of nurse practitioners agree that one of the roles of healthcare professionals is to provide their patients with information about dietary supplements, according to new research from the "Life...supplemented" 2009 Healthcare Professionals (HCP) Impact Study.

11 Mar 2010

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation’s largest pharmacy chains with 7,162 drugstores located throughout the United States.

11 Mar 2010

Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity

Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.

11 Mar 2010

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.

11 Mar 2010

FDA sponsoring workshops to increase rare disease treatment options

The Wall Street Journal: FDA is putting on workshops for pharmaceutical manufacturers to increase the pool of applicants for approved "orphan drugs," that treat rare diseases. Currently, there are about 7,000 so-called orphan diseases in the U.S. that have few or no FDA-approved treatments.

11 Mar 2010

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.

11 Mar 2010

Clinical trial shows eprotirome drug reduces blood cholesterol

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

11 Mar 2010

GSK to offer flexible drug pricing in middle-income countries

Drug maker GlaxoSmithKline (GSK) "plans to bolster earnings by selling to more people in middle-income countries after cutting prices in the world's poorest nations," Bloomberg/BusinessWeek reports.

11 Mar 2010

Pharmaceutical News

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

iReminder’s white paper highlights key developments in HPV vaccine compliance and marketing efforts

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Study uncovers mechanism facilitating motivation for alcohol after extended abstinence

Non-smoked medical cannabis products needed, says National Drug Control Policy Deputy Director

Advitech receives product licence for psoriasis treatment product

WHO issues new guidelines for malaria treatment

HGS, BioInvent International AB to discover, develop and commercialize therapeutic monoclonal antibodies

Watson Pharmaceuticals resolves Actos patent litigation

Forteo therapy may speed healing, improve patient outcomes after rotator cuff surgery

Comparative research lags far behind approval-driven evaluations

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Majority of nurse practitioners recommend dietary supplements for overall health and wellness

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

Cytokeratins 8 and 18 can strongly enhance breast cancer drug fulvestrant's anti-estrogenic activity

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

FDA sponsoring workshops to increase rare disease treatment options

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Clinical trial shows eprotirome drug reduces blood cholesterol

GSK to offer flexible drug pricing in middle-income countries

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News